CARB-X

Basilea Pharmaceutica announced Monday that the U.S. Biomedical Advanced Research and Development Authority has increased its total investment in the Swiss company’s ceftobiprole antibiotic candidate to $134.2 million.

The new tranche of $4.3 million will support a Phase 3 trial to evaluate the intravenous drug as an S. aureus bacteremia treatment, the press release said.

The Basel-based company won funding from CARB-X in May to develop a novel class of antibiotics against drug-…

Vaxcyte announced last week an additional $3.2 million CARB-X grant to support the company’s Investigational New Drug (IND) application for its novel universal Group A Streptococcus vaccine VAX-A1. CARB-X awarded the company $2.7 million for its initial funding period, per Vaxcyte’s press release.

Including future milestone payments, CARB-X’s VAX-A1 funding is worth up to $29.7 million to the California biotech.

Mentions:

France’s bioMérieux and Specific Diagnostics announced Tuesday that bioMérieux will distribute the latter’s newly introduced REVEAL Rapid AST system in Europe.

The deal is a boost to the California-based CARB-X grantee’s antibiotic susceptibility testing (AST) system, designed to quickly detect the emitted volatile molecules that are the first sign of bacterial growth in the blood and to determine which antibiotic is most suited to kill the bacteria.

The press release noted…

San Diego-based Qpex Biopharma announced last week that it has begun a Phase 1 study of QPX9003, its next-generation intravenously administered synthetic polymyxin for infections caused by drug-resistant gram-negative pathogens (including Acinetobacter species and P. aeruginosa).

In other AMR news, the U.S. National Institutes of Health has awarded HelixBind $3.3 million to support testing of its RaPID/BSI diagnostic platform for sepsis-related bloodstream infections, the biotech…

Boston University-led nonprofit CARB-X announced Tuesday that it will give Arizona-based Accelerate Diagnostics $578,000 (plus up to $2.1 million in milestones) to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections.

In other antimicrobial resistance news, Boston’s Selux Diagnostics announced Tuesday an additional $14.6 million award from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid…

CARB-X announced Tuesday that it will give Swiss biopharma BioVersys up to $4.3 million (plus up to $11 million in milestones) to develop new antibiotics to treat life-threatening infections caused by multidrug-resistant “ESKAPE” pathogens, including E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species.

BioVersys’ novel class of pyrrolocytosine small molecules have exhibited “robust coverage” of all relevant Gram-negative pathogens as well as other…

Boston University’s CARB-X consortium announced two new investments this week.

On Tuesday, the nonprofit said it will give Massachusetts-based Summit Therapeutics up to $4.1 million (plus up to $3.7 million in milestones) to develop its first-in-class SMT-738 antibiotic candidate for treating multidrug-resistant infections—specifically carbapenem-resistant Enterobacteriaceae (CRE) infections caused by pathogens including E. coli and K. pneumoniae. The funds will help advance the…

Maryland’s Integrated BioTherapeutics announced Wednesday a U.S National Institute of Allergy and Infectious Diseases contract worth up to $16.3 million to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease, and potentially bring the candidate to Phase 1.

The company previously won CARB-X support for its Staphylococcus aureus vaccine candidate, IBT-V02.

Boston University-led CARB-X announced Monday that it will give Australian diagnostics specialist SpeeDx up to $1.8 million (plus up to $1.9 million in milestones) to develop a one-hour combination test for chlamydia and gonorrhea that also determines the susceptibility of gonorrhea infections to common antibiotics. SpeeDX plans to combine its test with a portable, battery-operated device from Britain’s QuantuMDx, making the diagnostic ready for “remote or low-resource settings around the…

Boston University-led CARB-X announced Tuesday that it will give British diagnostics company GenomeKey $3 million (plus up to $6.5 million in milestones) to develop a four-hour test for sepsis. The diagnostic uses machine learning to identify bacterial species and test for antibiotic sensitivity, allowing clinicians to prescribe targeted drugs quickly and “reduce unnecessary antibiotic consumption,” the press release said.

Meanwhile, Massachusetts-based biotech X-Biotix announced…